Ultomiris (ravulizumab-cwvz) rapidly and sustainably eased symptom severity in adults with generalized myasthenia gravis (gMG), according to top-line data from a Phase 3 trial. Alexion Pharmaceuticals, the therapy’s developer, now plans to submit regulatory applications requesting approval of Ultomiris for gMG in the U.S., Europe, and Japan, later…
News
Nominations are now open for the worldwide 2022 Black Pearl Awards from Eurordis-Rare Diseases Europe. The 12 award categories recognize individual advocates, policy makers, researchers, organizations, and companies who work to make a difference for the global rare disease community. The deadline for nominations is Sept. 10…
People with generalized myasthenia gravis (MG) who have other diseases, or comorbidities, have a worse prognosis and are less likely to go into remission after thymus removal than those without other medical conditions. Those were the findings of a recent study that followed patients for about nine years after…
Harbour BioMed’s investigational therapy batoclimab (HBM9161) safely and rapidly eases symptoms and lowers the levels of harmful antibodies in adults with moderate-to-severe generalized myasthenia gravis (gMG), according to top-line data from a Phase 2 clinical trial in China. “The strong evidence generated from this study is quite exciting…
Women with myasthenia gravis (MG) given standard treatment improve significantly less in both objective and patient-reported outcome measures than do men, a study in Denmark with nearly five years of follow-up data reported. Notably, this sex difference was independent of age, disease duration, simultaneous health conditions (comorbidities), and prior…
A very rare case of a myasthenia gravis (MG) crisis caused by the Moderna COVID-19 vaccine was described recently by researchers at St. Joseph’s Regional Medical Center in Paterson, New Jersey. “Although numerous studies have observed the relationship between active COVID infections and MG exacerbations, no known studies or…
Patient dosing has begun in a Phase 1/2a clinical trial of NMD670, an investigational oral therapy by NMD Pharma aiming to improve motor abilities and quality of life for people with myasthenia gravis (MG). “We are pleased to announce the dosing of the first myasthenia gravis patient today…
At its first virtual investor event, biotech company Centogene set a bold mission: to cure 100 rare diseases within the next decade. A leader in the field of genetic diagnostics, Centogene used the June 22 event to present its strategic priorities, outlining its plans to speed the discovery…
Myasthenia Gravis (MG) Awareness Month may be wrapping up, but advocate Glenda Thomas is just getting started. Diagnosed at age 60 with the rare disease form known as MuSK MG, which attacks the muscle-specific tyrosine kinase receptors and can prevent muscles from contracting, Thomas now spends her waking hours…
Videonystagmography, a video-tracking system used to investigate balance disorders, can also detect eye muscle fatigue and recovery in myasthenia gravis (MG) patients, making it a potentially useful diagnostic test for MG, a study reported. The study, “A Novel Diagnostic Method for Myasthenia Gravis,” was published in…
Recent Posts
- Zilbrysq autoinjector found safe, effective in trials for use in gMG
- Dieting to be in better shape, not to have a perfect shape
- Mental health challenges are often an invisible aspect of MG
- New drug cemdisiran may offer gMG symptom relief with 4 doses a year
- Cell therapy KYV-101 eases symptoms in small trial for hard-to-treat gMG